TABLE 2.

Plasma Administration, Adverse Events/Safety, Follow-Up, and Outcomes

Characteristics	Convalescent Plasma, n = 59	Standard Plasma, n = 15	Wilcoxon Rank-Sum p or Hazard Ratio (95% CI)
Received any amount of assigned plasma, n (%)	58 (98)	14 (93)	–
Did not receive any plasma, n (%)	1 (2)	1 (7)	–
IgG antibody to severe acute respiratory syndrome coronavirus 2, reflectance light unit, median (IQR)			–
IgG plasma bag number 1	285 (240–331)	7 (2–11)	–
IgG plasma bag number 2	292 (250–335)	6 (3–14)	–
IgM plasma bag number 1	75 (38–129)	5 (4–12)	–
IgM plasma bag number 2	67 (51–122)	6 (5–11)	–
Infusion-related event, n (%)	1 (2)	0 (0)	–
Any SAE in the first 28 d, n (%)	16 (30)	4 (27)	–
Any SAE in the first 24 hr	2 (4)	1 (7)	–
Any SAE in days 2–7	8 (15)	2 (13)	–
Any SAE in days 8–28	10 (19)	1 (7)	–
Lost to follow-up at study completion (90 ± 10 d), n (%)	0 (0)	0 (0)	–
Outcomes
Primary outcome, ventilator-free days, median (IQR)	28 (2–28)	28 (0–28)	p = 0.86
Ventilator-free days in patients who were intubated at baseline	16 (0–23)	0 (0–0)	p = 0.10
Ventilator-free days in patients who were not intubated at baseline	28 (27.5–28)	28 (28)	p = 0.49
Secondary outcomes, n (%)
90-d all-cause mortality	16 (27)	5 (33)	0.74 (0.27–2.03)
90-d mortality in patients who were intubated at baseline	5 (45)	3 (100)	0.05 (0.01–0.46)
90-d mortality in patients who were not intubated at baseline	11 (23)	2 (17)	1.43 (0.32–6.46)
28-d all-cause mortality	14 (24)	4 (27)	0.80 (0.26–2.44)
World Health Organization ordinal scale 2 point change	12 (20)	3 (20)	0.75 (0.21–2.68)

IgG = immunoglobulin G, IgM = immunoglobulin M, IQR = interquartile range, SAE = serious adverse event.

Reflectance light units of antigen/antibody band in immunochromatographic test to severe acute respiratory syndrome coronavirus 2 (Fig. 1 for neutralizing antibody activity results).

SAE including death, grade 4 or greater organ failure, serious infusion reaction warranting termination of plasma infusion.

Dashes indicate no statistic for these variables.